IL322148A - פורמולציה של לניפיברנור - Google Patents

פורמולציה של לניפיברנור

Info

Publication number
IL322148A
IL322148A IL322148A IL32214825A IL322148A IL 322148 A IL322148 A IL 322148A IL 322148 A IL322148 A IL 322148A IL 32214825 A IL32214825 A IL 32214825A IL 322148 A IL322148 A IL 322148A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
lanifibranor
pharmaceutically acceptable
total weight
acceptable excipients
Prior art date
Application number
IL322148A
Other languages
English (en)
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of IL322148A publication Critical patent/IL322148A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL322148A 2023-01-19 2024-01-18 פורמולציה של לניפיברנור IL322148A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23305066 2023-01-19
PCT/EP2024/051107 WO2024153730A1 (en) 2023-01-19 2024-01-18 Lanifibranor formulation

Publications (1)

Publication Number Publication Date
IL322148A true IL322148A (he) 2025-09-01

Family

ID=85328867

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322148A IL322148A (he) 2023-01-19 2024-01-18 פורמולציה של לניפיברנור

Country Status (11)

Country Link
EP (1) EP4651942A1 (he)
JP (1) JP2026501899A (he)
KR (1) KR20250134679A (he)
CN (1) CN120857930A (he)
AR (1) AR131641A1 (he)
AU (1) AU2024208998A1 (he)
CL (1) CL2025002116A1 (he)
IL (1) IL322148A (he)
MX (1) MX2025008424A (he)
TW (3) TW202539643A (he)
WO (1) WO2024153730A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025238200A1 (en) * 2024-05-17 2025-11-20 Inventiva Treatment of a liver disease in patients with hepatic impairment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
FR3084254B1 (fr) 2018-07-27 2020-10-23 Inventiva Derives deuteres du lanifibranor
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022261410A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
MX2024001745A (es) 2021-08-12 2024-04-10 Crystal Pharmaceutical Suzhou Co Ltd Forma cristalina de lanifibranor, método de preparación del mismo y su uso.
TW202404966A (zh) 2022-04-05 2024-02-01 法商因文帝華公司 蘭尼菲諾(lanifibranor)之晶型

Also Published As

Publication number Publication date
TW202541797A (zh) 2025-11-01
TWI889153B (zh) 2025-07-01
AR131641A1 (es) 2025-04-16
JP2026501899A (ja) 2026-01-16
TW202435869A (zh) 2024-09-16
CL2025002116A1 (es) 2025-10-17
KR20250134679A (ko) 2025-09-11
TW202539643A (zh) 2025-10-16
MX2025008424A (es) 2025-08-01
AU2024208998A1 (en) 2025-08-21
EP4651942A1 (en) 2025-11-26
WO2024153730A1 (en) 2024-07-25
CN120857930A (zh) 2025-10-28

Similar Documents

Publication Publication Date Title
ES2167921T5 (es) Comprimido multiparticulado perfeccionado de disgregación rápida
US20200323776A1 (en) Diclofenac formulations and methods of use
US20070275075A1 (en) Ezetimibe compositions
NO20110090L (no) Stabil fast oral sammensetning omfattende levodopa, carbidopa, og entacapon
EA019614B1 (ru) Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения
IL322148A (he) פורמולציה של לניפיברנור
BRPI0609497A2 (pt) formulações aprimoradas de fenofibrato
US20080038332A1 (en) Stable pharmaceutical formulation comprising atorvastatin calcium
ES2288117B1 (es) Composicion farmaceutica solida de gabapentina.
JP5171143B2 (ja) 用時溶解型ビタミン製剤及びその製造方法
KR101609105B1 (ko) 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물
CN112516097B (zh) 一种苯磺酸左旋氨氯地平组合物
WO2024206885A1 (en) Oral mucosal formulations of aspirin
WO1999020277A1 (en) Rapidly soluble drug composition
CA3238703A1 (en) A film coated tablet comprising micronized tofacitinib
WO2022263510A1 (en) Granulate composition comprising nilotinib
EP3675832A1 (en) Fast self dispersible dosage forms of deferasirox